Answers are grounded in this paper and cite their sources.
Background: Evidence on the depth of molecular response and long-term tolerability of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase (CML-CP) remains limited. Methods: Children with newly diagnosed BCR::ABL1-positive CML-CP received nilotinib 230 mg/m2 twice daily in a prospective multicenter cohort. BCR::ABL1 on the International Scale (IS) was assessed at scheduled visits; major molecular response (MMR), MR4, and MR4.5 were summarized among patients with data at cycles 3, 6, and 12. Adverse events were graded using Common Terminology Criteria for Adverse Events version 5.0. Nilotinib trough concentrations were assessed in 54 patients using morning predose blood samples analyzed at a specialized third-party clinical laboratory. Results: Ninety-two children were included (median age, 10.3 years [IQR, 7.6–12.5]); 64 (69.6%) were male. MMR was recorded in 22/78 (28.2%), 37/64 (57.8%), and 40/50 (80.0%) evaluable patients at cycles 3, 6, and 12, respectively. At cycle 12, 19/50 (38.0%) had MR4 and 15/50 (30.0%) had MR4.5. At a median follow-up of 1.79 years (IQR, 1.09–2.83), the estimated 2-year event-free survival was 96.4% (95% CI, 86.1–99.1%). Common adverse events included ALT elevation (60/90, 66.7%), myelosuppression (43/87, 49.4%), hyperbilirubinemia (35/89, 39.3%), and rash (29/92, 31.5%). At cycle 6, nilotinib trough concentration showed a modest inverse correlation with BCR::ABL1 transcript levels (Spearman ρ = −0.329, p = 0.044). Conclusions: Frontline nilotinib produced clinically meaningful molecular responses in evaluable pediatric patients with CML-CP. The observed association between trough concentration and molecular response was modest and exploratory and requires prospective validation.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: